Keyphrases
Persistent Infection
100%
Immunocompromised Patients
100%
COVID-19
100%
Successful Treatment
100%
Rheumatoid Arthritis
50%
Immune Evasion
50%
Virus Evolution
50%
SARS-CoV-2 Infection
50%
Anti-B Cell Therapy
50%
Corticosteroids
25%
Viral Genome
25%
Immunoglobulin
25%
Next-generation Sequencing
25%
Fatal Outcome
25%
Viral
25%
Clinical Course
25%
Pseudomonas Aeruginosa (P. aeruginosa)
25%
High Dose
25%
Immune System
25%
Reconstitution
25%
Bacterial Infection
25%
Treatment Course
25%
Amplicon
25%
Sinusitis
25%
Successful Outcome
25%
Cytomegalovirus
25%
Opportunistic Pathogens
25%
Cytomegalovirus Viremia
25%
Respiratory Symptoms
25%
Nasopharyngeal
25%
Immune Resistance
25%
Rituximab
25%
Nasopharyngeal Swab
25%
Cytomegalovirus Pneumonitis
25%
COVID-19 Infection
25%
Spike mutations
25%
Remdesivir
25%
Within-host Evolution
25%
SARS-CoV-2 Lineages
25%
SARS-CoV-2 PCR
25%
Baricitinib
25%
Cryptogenic Organizing Pneumonia
25%
Evolution over Time
25%
Persistent COVID-19
25%
Secondary Bacteremia
25%
Medicine and Dentistry
Severe Acute Respiratory Syndrome Coronavirus 2
100%
Immunocompromised Patient
100%
Persistent Infection
100%
Infection
42%
Rheumatoid Arthritis
28%
COVID-19
28%
B Cell
28%
Cytomegalovirus
28%
Inflammatory Arthritis
28%
Virus
28%
Immunoglobulin
14%
Pathogen
14%
Fatality
14%
Pseudomonas aeruginosa
14%
Drug Megadose
14%
Mixed Infection
14%
Viremia
14%
Disease Course
14%
Immune Evasion
14%
Sinusitis
14%
Bronchiolitis Obliterans Organizing Pneumonia
14%
Amplicon
14%
Rituximab
14%
Bloodstream Infection
14%
Next Generation Sequencing
14%
Nasopharyngeal Swab
14%
Remdesivir
14%
Immune System
14%
Baricitinib
14%
Immunology and Microbiology
Immunocompromised Patient
100%
Severe Acute Respiratory Syndrome Coronavirus 2
100%
Infection
100%
Lineages
28%
B Cell
28%
Virus Evolution
28%
COVID-19
28%
Inflammatory Arthritis
28%
Cytomegalovirus
28%
Infectious Agent
14%
Next Generation Sequencing
14%
Intravenous Immunoglobulin
14%
Pseudomonas aeruginosa
14%
Drug Megadose
14%
Coinfection
14%
Immune Evasion
14%
Viremia
14%
Spike
14%
Amplicon
14%
Pneumonitis
14%
Sinusitis
14%
Rituximab
14%
Immune System
14%
Ribonucleic Acid
14%
Pharmacology, Toxicology and Pharmaceutical Science
Persistent Infection
100%
SARS Coronavirus
100%
Immunocompromised Patient
100%
Infection
42%
Rheumatoid Arthritis
28%
Cytomegalovirus
28%
Inflammatory Arthritis
28%
Fatality
14%
Infectious Agent
14%
Immunoglobulin
14%
Pseudomonas aeruginosa
14%
Disease Course
14%
Viremia
14%
Sinusitis
14%
Mixed Infection
14%
Bronchiolitis Obliterans Organizing Pneumonia
14%
Rituximab
14%
Bloodstream Infection
14%
Remdesivir
14%
Baricitinib
14%